Populations	Phase 1	Phase 2	Approved	Current Status
Advanced Malignant PEComa	nab-sirolimus			First FDA approved therapy for advanced malignant PEComa Based on Ph 2 Registrational AMPECT Trial
Advanced or recurrent endometrioid-type endometrial cancer	nab-sirolimus + letrozole			Open-label study currently enrolling patients Initial data expected in 2024

Drug	Stage	Current Status
Advanced Malignant PEComa nab-sirolimus	Approved	First FDA approved therapy for advanced malignant PEComa Based on Ph 2 Registrational AMPECT Trial
Advanced or recurrent endometrioid-type endometrial cancer nab-sirolimus + letrozole	Phase 2	Open-label study currently enrolling patients Initial data expected in 2024

Evaluation of additional new nab-sirolimus and combination trials ongoing.